Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | AHCY | P23526 | 7/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815870 | 0.86 | ADORA2A (0.71) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL1665392 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL5801729 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL6690627 | 0.79 | ADORA2A (0.56) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL4541360 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL3306409 | 0.77 | AHCY (0.65) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL4343213 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL9255634 | 0.73 | ADORA2A (0.49) | ADORA2AADORA1EGFRSRCKDR | |
| Hydrochloric Acid SCHEMBL9778348 | 0.73 | ADORA2A (0.75) | ADORA2AADORA1KDR | |
| Hydrochloric Acid SCHEMBL9778362 | 0.73 | ADORA2A (0.75) | ADORA2AADORA1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043083-A1 | DNA-BARCODED ANTIGEN MULTIMERS AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4276198-B1 | NUCLEIC ACID SYNTHESIS AND SEQUENCING USING TETHERED NUCLEOSIDE TRIPHOSPHATES | UNIV CALIFORNIA (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12435356-B2 | Target reporter constructs and uses thereof | REDVAULT BIOSCIENCES, LP (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240401099-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240368682-A1 | SYSTEMS AND METHODS FOR CLONAL REPLICATION AND AMPLIFICATION OF NUCLEIC ACID MOLECULES FOR GENOMIC AND THERAPEUTIC APPLICATIONS | REDVAULT BIOSCIENCES LP (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240191298-A1 | DNA-BARCODED ANTIGEN MULTIMERS AND METHOD OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4372102-A2 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | RedVault Biosciences, LP (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240140977-A1 | REVERSIBLE TERMINATORS | ANSA BIOTECHNOLOGIES, INC. | 2024-05-02 | — | — | US | disclosed |
| EP-3464628-B1 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | REDVAULT BIOSCIENCES LP (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20240026436-A1 | METHODS AND COMPOSITIONS FOR THE AMPLIFICATION OF MRNA | BAYLOR COLLEGE OF MEDICINE (US) | 2024-01-25 | — | — | US | disclosed |
| EP-2755984-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Lasergen, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2013040257-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | ADORA2A 274/4885ADORA1 251/4885EGFR 2738/4885 |
| US-20240401099-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | RNGTT, DNTT, TYMP | ADORA2A 398/4885ADORA1 377/4885EGFR 3630/4885 |
| US-20260043083-A1 | DNA-BARCODED ANTIGEN MULTIMERS AND METHODS OF USE THEREOF | HLA-DRB1, MICA, CD74 | ADORA2A 2764/4885ADORA1 2754/4885EGFR 2097/4885 |
| US-20240140977-A1 | REVERSIBLE TERMINATORS | RNGTT, TYMP, TYMS | ADORA2A 2953/4885ADORA1 3082/4885EGFR 4523/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | ADORA2A 274/4885ADORA1 251/4885EGFR 2738/4885 |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | ADORA2A 1117/4885ADORA1 1196/4885EGFR 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.